Winstead Welcomes New Shareholder Andrew Rosell

Friday, January 16, 2015

Winstead PC welcomes Andrew Rosell, a shareholder in the corporate, securities/mergers and acquisitions practice group. Rosell was previously a partner at Kelly Hart & Hallman LLP. He will practice in Winstead’s Fort Worth office.

“I am excited to bring my practice to Winstead’s Fort Worth office and work with their deep bench of attorneys serving clients from every major investment center in Texas and Charlotte,” said Rosell. “It will be a great opportunity to expand Winstead’s services.” More >>

Tags:  Winstead PC | Fort Worth

Emerging growth and venture capital lawyer Jonathan Axelrad joins DLA Piper in San Francisco

Friday, January 16, 2015

DLA Piper announced today that Jonathan Axelrad has joined the firm’s Corporate and Finance practice as a partner in the San Francisco office.

Axelrad represents emerging growth companies throughout their life cycle. He also represents venture capital and private equity funds that invest in early-stage companies, assisting in financings, mergers and acquisitions, and corporate governance issues. More >>

Tags:  DLA Piper | San Francisco

Open Text Corporation $800 Million Notes Offering

Friday, January 16, 2015

Davis Polk advised Barclays Capital Inc. as representative of the several initial purchasers in connection with a Rule 144A/Regulation S offering of $800 million aggregate principal amount by Open Text Corporation (“OpenText”) of its 5.625% senior notes due 2023. The notes are guaranteed by certain subsidiaries of OpenText. Barclays Capital Inc., Morgan Stanley & Co. LLC, RBC Capital Markets, LLC and Citigroup Global Markets acted as joint bookrunners in the offering. The offering was OpenText’s debut offering in the capital markets. More >>

Tags:  New York

Baker Botts Represents Depomed in $1.05 Billion Acquisition of the U.S. Rights to the NUCYNTA Franchise from Janssen Pharmaceuticals

Friday, January 16, 2015

Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, and NUCYNTA® (tapentadol), an immediate release version of tapentadol. The deal will make NUCYNTA the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals. More >>

Tags:  Baker Botts L.L.P. | Palo Alto

Arnall Golden Gregory Advised Griffin-American Healthcare REIT II in its $4 Billion Merger with NorthStar Realty Finance Corp.

Friday, January 16, 2015

Arnall Golden Gregory LLP advised Griffin-American Healthcare REIT II, Inc. in connection with the merger of the REIT with NorthStar Realty Finance Corp. (NYSE: NRF). The merger became effective on December 3, 2014. Arnall Golden Gregory served as lead healthcare regulatory counsel for Griffin-American REIT II in connection with the merger, and has served as Griffin-American’s REIT counsel advising on matters pertaining to REIT assets acquired in various transactions. More >>

Tags:  Arnall Golden Gregory LLP | Atlanta

Suzanne Brown Walsh Joins Murtha Cullina LLP

Thursday, January 15, 2015

Murtha Cullina LLP is pleased to welcome a new Partner, effective January 1, 2015.

Suzanne Brown Walsh is joining Murtha Cullina’s Trusts and Estates Department where she will practice estate planning, particularly for families of children with special needs, and elder law and estate and trust administration. More >>

Tags:  Murtha Cullina, LLP | Hartford

Roark Capital Closes Fund IV at $2.5 Billion

Thursday, January 15, 2015

Paul, Weiss client Roark Capital Group, an Atlanta-based private equity firm, announced the closing of Roark Capital Partners IV LP, with $2.5 billion in total investor limited partner commitments. Fund IV closed at its hard cap. More >>

Tags:  New York